Prepare for a career in biopharmaceuticals.
Research the expression, purification and characterization of biotherapeutics.
Transform research into products that are ready for clinical testing.
What we do...
The BPDF develops vaccines and biotherapeutics derived from recombinant yeast and bacterial expression systems under current Good Manufacturing Practices and Good Laboratory Practices.
Who we serve...
We serve both public and private sector clients. Our products range from vaccines against biological warfare agents to biotherapeutics for the treatment of cancer, AIDS and other illnesses.
UCARE Student Travis Jackson Returns for his Second Year at the BPDF
This fall, sophomore Travis Jackson begins his second year in the Undergraduate Creative Activities and Research Experience program at the BPDF. The UCARE Program, funded by the Pepsi Endowment, offers undergraduate students opportunities to work with faculty members in UNL research or creative activities.
The BPDF in the Fight Against HIV
Mintaka Foundation funds BPDF to create HIV resistant topical cream for women.
With $3.8 million in new funding from the Mintaka Foundation of Medical Research supported by the Wellcome Trust, the UNL BPDF is developing a process to manufacture a stable and affordable microbicide to protect women from contracting and spreading HIV. Read more about the contract.
Current Good Manufacturing Practices...
...are FDA regulations for the development and manufacture of pharmaceuticals. More info: FDA: Facts About Current Good Manufacturing Practices.
Undergraduate students Taylor Laughlin (left) and Katherine Rilett work in the BPDF Fermentation Development Laboratory
New 150L cGMP Facility
An $11.2 million Phase I/II cGMP pilot plant was completed on Dec 31, 2008. Designed and built by AES Clean Technology and BioKinetics, Inc, it has 6,000 square feet of cleanrooms and 7,000 square feet of support space. Commissioning and validation is underway. More about the new facility.